Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2/3 × Recurrence × Breast × Clear all

Phase

Phase 2 20 Phase 1 20 Phase NA 15 Phase 3 10 Phase 1/2 8 Phase EARLY_PHASE1 1 Phase 2/3 1

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 6 CNS 4 Other hematologic neoplasm 3 Head & Neck 3 Genitourinary 3 Thoracic 2 Gastrointestinal 2 Myeloid 1 Breast 1

Conditions

Breast Neoplasms 90 Triple Negative Breast Neoplasms 5 Neoplasm Metastasis 4 HER2-positive Breast Cancer 4 Neoplasms 3 Motor Activity 3 Inflammatory Breast Neoplasms 3 Prostatic Neoplasms 2 Lung Neoplasms 2 Fatigue 2 Depression 2 Carcinoma, Ductal, Breast 2 Breast Carcinoma In Situ 2 Anxiety Disorders 2 Urinary Incontinence 1 To Evaluate the Effectiveness of GM1 in the Prevention of Albumin-paclitaxel Therapy Induced Peripheral Neuropathy in Breast Cancer Patients 1 Smoking 1 Sleepiness 1 Sarcoma 1 Recurrence 1 Radiodermatitis 1 Radiation Injuries 1 Peripheral Nervous System Diseases 1 Parasomnias 1 Pain 1 Ovarian Neoplasms 1 Orgasm 1 Obesity 1 Microcephaly, Primary Autosomal Recessive, 6 1 Metastatic Breast Cancer With Bone Involvement 1

Interventions

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03315364 2024-07-25

OPTIMAL

Daehwa Pharmaceutical Co., Ltd.

Phase 2/3 Active not recruiting

Breast Neoplasms, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon ⚡